HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $33 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) and maintained a price target of $33.
September 14, 2023 | 10:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Crinetics Pharmaceuticals (NASDAQ:CRNX) has had its 'Buy' rating reiterated and its price target maintained at $33 by HC Wainwright & Co.
The reiteration of a 'Buy' rating and maintenance of a $33 price target by HC Wainwright & Co. is a positive signal for Crinetics Pharmaceuticals. This could potentially lead to an increase in investor confidence and a short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100